EF Hutton analyst Anthony Butler reiterated a Buy rating on IN8bio (INAB – Research Report) today and set a price target of $8.00. The company’s shares closed last Friday at $3.15.
According to TipRanks, Butler is a 2-star analyst with an average return of 0.3% and a 42.70% success rate. Butler covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Rain Therapeutics, and Aravive.
Currently, the analyst consensus on IN8bio is a Strong Buy with an average price target of $11.33.
See today’s best-performing stocks on TipRanks >>
INAB market cap is currently $93.71M and has a P/E ratio of -2.34.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IN8bio Inc is a clinical-stage biotechnology company. It is focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
Read More on INAB:
- IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
- IN8bio to present data on potential of INB-400 to target ovarian cancer
- IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting
- IN8bio appoints Graff to board of directors
- IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting
